Bharat Biotech’s iNCOVACC To Be Launched On 26 January

On January 26, Republic Day, our nasal vaccine will be formally introduced, Ella announced at a gathering on Saturday

Bharat Biotech, a domestic manufacturer of vaccines, will debut its first intranasal covid-19 vaccine, called iNCOVACC, on January 26. The company's chairman and managing director Krishna Ella made the announcement last week.

On January 26, Republic Day, our nasal vaccine will be formally introduced, Ella announced at a gathering on Saturday.

The nasal covid vaccination has already received official approval for use in people older than 18 years, and it will also be given as a heterologous booster dose.

For patients who have already received Covishield and Covaxin, the nasal vaccine can be used as a heterologous booster dose.

The first intranasal vaccine in the history of the world to get approval for both primary series and heterologous booster is iNCOVACC.

The shot is going to be a part of the covid-19 list of vaccine and will be accessible in private hospitals.

According to Bharat Biotech, the intranasal vaccine will cost 325 per shot for government purchases and 800 per shot for private immunisation facilities.

However, neither the state nor the central governments have made any requests for procurement, revealed sources close to the company. Prior to this, a primary 2-dose schedule for ages 18 and older in an emergency circumstance had been approved under restricted use.

At 14 trial sites throughout India, the vaccine's Phase III trials were carried out on 3,100 people to assess its immunogenicity and safety.

Once it has the necessary licences from the other countries, Hyderabad-based companies also intend to export iNCOVACC there.